Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03330847
Title To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

triple-receptor negative breast cancer

Therapies

Adavosertib + Olaparib

Olaparib

AZD6738 + Olaparib

Age Groups: adult | senior
Covered Countries USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.